Hera Biotech

Executive Summary

Hera Biotech is a US-based diagnostics company developing non-invasive, tissue-based diagnostic technologies for women's health, leveraging an AI-powered platform to detect and stage endometriosis and diagnose cervical cancer at the point of care. Founded in 2018 and headquartered in San Antonio, the company aims to replace invasive surgical biopsies and traditional cytology with accurate, less burdensome alternatives. By integrating its tools into OB-GYN, fertility, and drug discovery workflows, Hera seeks to improve diagnostic accuracy and accelerate treatment decisions. The company's platform addresses a significant unmet need: endometriosis affects approximately 10% of reproductive-age women, yet diagnosis is delayed 7–10 years on average due to reliance on surgery. Similarly, cervical cancer screening suffers from high false-positive rates and low follow-up compliance. Hera's technology promises to enhance early detection, reduce patient discomfort, and lower healthcare costs. The company is privately held and has not disclosed funding amounts, but its focus on commercializing non-invasive diagnostics positions it in a high-growth market. Hera Biotech's proprietary AI algorithms analyze tissue samples obtained via minimally invasive methods, enabling objective, reproducible results that could streamline clinical decision-making. With strong intellectual property and a clear regulatory pathway, the company is poised to disrupt the women's diagnostics landscape.

Upcoming Catalysts (preview)

• Q4 2026Pivotal clinical trial results for endometriosis diagnostic60% success
• Q2 2026FDA breakthrough device designation or 510(k) submission50% success
• H1 2026Strategic partnership with a major OB-GYN or fertility clinic network70% success